Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 35 Glioblastoma 24 Carcinoma, Non-Small-Cell Lung 21 Ovarian Neoplasms 14 Carcinoma, Hepatocellular 14 Brain Neoplasms 14 Carcinoma, Renal Cell 13 Pancreatic Neoplasms 12 Neoplasms 10 Neoplasm Metastasis 10 Glioma 10 Breast Neoplasms 10 Colonic Neoplasms 8 Astrocytoma 8 Melanoma 7 Uterine Cervical Neoplasms 6 Rectal Neoplasms 6 Liver Neoplasms 6 Gliosarcoma 6 Endometrial Neoplasms 6 Stomach Neoplasms 5 Lung Neoplasms 5 Fallopian Tube Neoplasms 5 Colorectal Cancer Metastatic 5 Advanced Solid Tumors 5 Squamous Cell Carcinoma of Head and Neck 4 Prostatic Neoplasms 4 Oligodendroglioma 4 Triple Negative Breast Neoplasms 3 Small Cell Lung Carcinoma 3

Interventions

Cyclophosphamide 2 sodium thiosulfate 1 repotrectinib 1 pralsetinib 1 lutetium Lu 177 dotatate 1 fludarabine phosphate 1 fludarabine 1 bintrafusp alfa protein, human 1 Thrombopoietin 1 Plicamycin 1 Melphalan 1 Mannitol 1 ICE protocol 5 1 Etoposide 1 Drug Therapy 1 Cytosine Deaminase 1 Carboplatin 1 Bevacizumab 1 Azacitidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neoplasms, Germ Cell and Embryonal × Bevacizumab × Clear all

NCT01966913 2019-02-19

TAXIFIII

Assistance Publique - Hôpitaux de Paris

Phase 1/2 Unknown

Neoplasms, Germ Cell and Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon ⚡